Qualitative and quantitative approaches are important issues in field of carcinogenic risk assessment of the genotoxic carcinogens. Herein, we provide quantitative data on lowdose hepatocarcinogenicity studies for three genotoxic hepatocarcinogens: 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx), 2-amino-3-methylimidazo[4,5-f]quinoline (IQ) and N-nitrosodiethylamine (DEN). Hepatocarcinogenicity was examined by quantitative analysis of glutathione S-transferase placental form (GST-P) positive foci, which are the preneoplastic lesions in rat hepatocarcinogenesis and the endpoint carcinogenic marker in the rat liver medium-term carcinogenicity bioassay. We also examined DNA damage and gene mutations which occurred through the initiation stage of carcinogenesis. For the establishment of points of departure (PoD) from which the cancer-related risk can be estimated, we analyzed the above events by quantitative no-observed-effect level and benchmark dose approaches. MeIQx at low doses induced formation of DNA-MeIQx adducts; somewhat higher doses caused elevation of 8-hydroxy-2′-deoxyquanosine levels; at still higher doses gene mutations occurred; and the highest dose induced formation of GST-P positive foci. These data indicate that early genotoxic events in the pathway to carcinogenesis showed the expected trend of lower PoDs for earlier events in the carcinogenic process. Similarly, only the highest dose of IQ caused an increase in the number of GST-P positive foci in the liver, while IQ-DNA adduct formation was observed with low doses. Moreover, treatment with DEN at low doses had no effect on development of GST-P positive foci in the liver. These data on PoDs for the markers contribute to understand whether genotoxic carcinogens have a threshold for their carcinogenicity. The most appropriate approach to use in low dose-response assessment must be approved on the basis of scientific judgment.
Introduction
Carcinogen risk assessments identify the risk from exposure to carcinogens prior to extensive human exposure. Identification of most carcinogens is done by using 2-year carcinogenicity tests in rodents. To assess risk in humans, carcinogenic response curves obtained from these tests are used. Importantly, the carcinogenicity at low doses of carcinogens is generally extrapolated from the carcinogenicity data obtained using high doses. To obtain statistically acceptable data, chemicals are generally used in carcinogenicity tests at high doses, including the maximum tolerated dose. The principle role of assessing risk posed to humans for exposure to genotoxic carcinogens uses non-threshold approaches: the curves generated by non-threshold approach modeling are S-shaped or linear low-dose straight lines that reach zero. This putative 'non-threshold concept' of genotoxic carcinogenicity reflects the idea that a single event caused by a genotoxic carcinogen can have a positive influence on cancer development. However, the biological adaptive response to carcinogen suggests that carcinogenic thresholds should exist, even for genotoxic carcinogens (1, 2) .
In qualitative analysis, the accepted mechanism of genotoxic carcinogenesis is based on the ability of most chemical genotoxic carcinogens to be metabolised within the cell to their active forms, known as ultimate carcinogens, before they are able to exert their carcinogenic activity. The ultimate carcinogens formed from genotoxic carcinogens bind covalently to DNA, forming adducts. These adducts can interfere with normal DNA metabolism, leading to DNA mutations. However, these DNA adducts are efficiently repaired by the cell. Still, for any particular adduct there is the possibility of misrepair or replication of damaged DNA resulting in fixation of a mutation into the cell's genome. Therefore, there is a finite risk of mutation arising from a single adduct. Next, at the level of DNA mutation, carcinogen-DNA adduct formation is essentially random in the euchromatic DNA; consequently, only a minute fraction of the mutations arising from these adducts will actually occur in a gene and have an effect on the cell, and only a very small fraction of these will be carcinogenic. In practical terms then, only a minute fraction of adducts actually give rise to DNA mutations and only a minute fraction of these mutations will affect the cell. As the number of adducts increases, however, the possibility of mutations occurring increases and mutated cells eventually begin to appear (3). This is especially relevant as the number of adducts becomes greater than the capacity of the cell to repair this damage. Most mutated cells will die due to metabolic dysfunctions or be eliminated by irreversible senescence or apoptosis, but it is possible that some will survive and be viable. In the two-stage chemical carcinogenesis model, this sequence of events is thought to occur during the initiation stage. Cell proliferation enhances the ability of initiated cells to form preneoplastic lesions and to develop into tumours, benign and then malignant. Evidence indicates that in the process of carcinogenesis, some of preneoplastic lesions may spontaneously disappear, presumably due to the biological adaptive response, resulting in apoptosis and necrosis. The development from initiated cells into tumours is the promotion stage of the two-stage chemical carcinogenesis model. Quantitative analysis of the key events in genotoxic carcinogenesis deepens understanding of low dose carcinogenicity mechanisms.
For detection of carcinogenicity, the standard method is longterm carcinogenicity testing in two rodent species, such as rats and mice, with at least three dose levels, and in-life study termination at 18 months for mice and 24 months for rats (4) . However, such tests are extremely time consuming, laborious and expensive. This is particularly true when examining the effects of low doses of suspected carcinogens since many animals are required to reliably determine whether the low doses used are in fact able to induce an increase in tumour formation. In practical terms, it is currently impossible to examine the carcinogenicity of all suspect compounds using longterm carcinogenicity tests. Therefore, recently, alternative methods to the long-term carcinogenicity testing in which preneoplastic lesions are accepted as endpoint markers for the assessment of carcinogenicity has been proposed (5) . Results are obtained from this in vivo medium-term bioassay of carcinogens in a matter of weeks rather than, as with long-term testing, many months.
For extrapolation of genotoxic carcinogenicity study results to human, there are five items to point out: (i) Qualitative analysis only to classify into genotoxicity or non-genotoxicity may be inadequate for carcinogenic risk assessment. (ii) Qualitative assessment is desirable in analysis for carcinogenicity, particularly at low doses.
Quantitative assessment also can contribute to the analysis for low doses. (iii) In point of view on weight of evidence, in vivo data are more valuable than in vitro results in the quantitative analysis. (iv) Point of departure (PoD) can be used for quantitative analysis of genotoxicity and carcinogenicity dose-response data. (v) Differences of PoDs for qualitative markers of in vivo carcinogenic mechanism for genotoxic carcinogens may elicit definite conclusion on the basis of scientific evidence.
Herein, we provide our data from low-dose mediumterm carcinogenicity studies for genotoxic carcinogens such as 2-amino-3,8-dimethylimidazo[4,5-f] quinoxaline (MeIQx), 2-amino-3-methylimidazo[4,5-f]quinoline (IQ) and N-diethylnitroamine (DEN). Hepatocarcinogenicity was examined by quantitative analysis of glutathione S-transferase placental form (GST-P) positive foci which are considered preneoplastic lesions in rat hepatocarcinogenesis and the endpoint carcinogenic marker in the rat liver mediumterm carcinogenicity bioassay. We also examined DNA damage and gene mutation that cells typically acquire as they move through the initiation and promotion stages of carcinogenesis. In concept of putative existence of carcinogenic threshold, we analysed the above data by quantitative approaches, no-observed-effect level (NOEL) and benchmark dose (BMD) for establishment of PoDs from which the exposure-related risk can be estimated. To obtain BMD, we used EPA's Benchmark Dose Software (BMDS) (US EPA 2014).
Low dose carcinogenicity of MeIQx in the rat liver
MeIQx is a heterocyclic amine contained in fried meat and fish. MeIQx at doses of 100-400 ppm in the diet is carcinogenic in the rat liver (6) (7) (8) . To investigate the effect of exposure to low doses of MeIQx, 1145 21-day-old male F344 rats were divided into seven groups and administered MeIQx in the diet at doses of 0, 0.001, 0.01, 0.1, 1, 10 ppm (low dose groups) and 100 ppm (high dose group) for 4-32 weeks (6) .
The induction of the liver GST-P positive foci after treatment with various doses of MeIQx for 16 and 32 weeks is shown in Figure 1 . The numbers of GST-P positive foci were not significantly elevated in the 0.001-10 ppm MeIQx groups, but a statistically significant increase was detected in the 100 ppm group (Table 1 same results were observed when the treatments with MeIQx were continued for 32 weeks. MeIQx is metabolized in the liver cells to an ultimate carcinogen capable of covalently binding DNA. The formation of MeIQx-DNA adducts at week 4 was below the limit of detection in 0 and 0.001 ppm. The adducts were induced by administration of 0.01 ppm and higher doses of MeIQx, and this induction was dose-dependent and statistically significant in 100 ppm dose group compared to 0.01 ppm (Figure 2A ). Importantly, in recent studies, NOEL for DNA adducts formation in the rat liver with prolonged dosing of hepatocarcinogen such as 2-acetylaminofluorene has been reported (9, 10) .
DNA is subject to constant oxidative damage from endogenous oxidants. 8-hydroxy-2′-deoxyguanosine (8-OHdG) is a marker for oxidative DNA damage and its levels rise as a cell becomes more metabolically active. 8-OHdG levels at week 4 were unaffected by treatment with 0.001, 0.01 or 0.1 ppm MeIQx, but became significantly elevated after treatment with MeIQx at doses of 1, 10 and 100 ppm ( Figure 2B) .
Based on the results of MeIQx exposure-related events, in the present study the NOEL was estimated to be 0.1 ppm for 8-OHdG and 10 ppm for GST-P positive foci. Due to limitations in detection of DNA adducts, we were unable to determine whether a threshold dose of MeIQx was required for MeIQx-DNA adduct formation. However, the adduct levels presumably have been very low (under 0.01 ppm). On the other hand, the derived BMDL 1SD values were: 4.1 ppm for DNA adducts; 0.07 ppm for 8-OHdG; 22.0 ppm for GST-positive foci 16 weeks ; 15.1 ppm for GST-positive foci 32 weeks . Unexpectedly, the BMDL 1SD 8-OHdG formation level was clearly lower than that of DNA adducts. In addition, it should be noted that in case of GST-P positive foci BMDL 1SD was greater than NOEL. The BMLD ISD values were the most applicable for our data as the results of our experiments were expressed as mean and SD, but not as percentage.
We also examined mutation of the lacI gene and induction of GST-P positive foci in the livers of Big Blue® rats (7). Forty male Big Blue® rats were divided into seven groups and administered MeIQx in the diet at doses of 0, 0.001, 0.01, 0.1, 1, 10 and 100 ppm for 16 weeks. A statistically significant elevation of lacI gene mutation level was detected in 10 and 100 ppm groups ( Figure 3A) . On the other hand, formation of GST-P positive foci was statistically significantly induced by administration of 100 ppm but not 10 ppm or lower MeIQx doses ( Figure 3B ). The NOEL was estimated to be 1 ppm for mutation and 10 ppm for GST-P positive foci. The BMDL 1SD values were: 6.98 ppm for mutation and 6.72 ppm for GST-P positive foci. Unexpectedly, the value of BMDL 1SD for the mutation frequency was higher than that of NOEL.
Low dose hepatocarcinogenicity of IQ in the rat liver
The heterocyclic amine IQ is a carcinogen contained in seared meat and fish, and exerts its carcinogenicity in the rat liver (11) . We investigated the hepatocarcinogenicity of IQ in the rat when applied at doses of 0.001-100 ppm (11) . A total of 1595 male F344 rats were divided into seven groups and administered with IQ at doses of 0, 0.001, 0.01, 0.1, 1, 10 and 100 ppm in the diet for 16 weeks.
We found that IQ doses of 1 ppm and below did not induce GST-P positive foci in the rat liver, while doses of 10 and 100 ppm had opposite effect ( Figure 4A ). Like MeIQx, IQ is a genotoxic compound which is metabolized in cells to an ultimate carcinogen capable of covalently binding DNA. Formation of IQ-DNA adducts was induced by 4 weeks IQ administration at doses of 0.01 ppm and higher ( Figure 4B ). Thus, similarly to MeIQx, DNA adduct formation was observed after treatment with IQ at low doses, while doses required to induce GST-P positive foci were much higher.
During the establishment of PoD for IQ exposure-related events, the NOEL for GST-P positive foci was considered 1 ppm, while NOEL for IQ-DNA adducts is likely to be under the 0.01 ppm. The BMDL 1SD was 0.09 ppm for IQ-DNA adducts and 62.0 ppm for GST-P positive foci. Unexpectedly, the value of BMDL 1SD for GST-P positive foci was clearly higher than that of NOEL.
These results argue for a threshold dose for IQ hepatocarcinogenicity in rats.
Low dose hepatocarcinogenicity of DEN in the rat liver
N-nitrosocompounds such as DEN are synthesized in the stomach through the reaction of secondary amines and nitrites in the diet. They are also found as contaminants of a variety of manufactured food products. Peto et al. (12) investigated the carcinogenicity of DEN using 2040 male and 2040 female Colworth rats. DEN at doses of 0.033 to 16.896 ppm was administered to rats in their drinking water and induction of liver tumours was found to be dependent on the applied doses of DEN, and at lower doses a linear dose-tumour incidence relationship was observed. Therefore, it was concluded that DEN had no threshold for its carcinogenicity in the rat liver.
We have re-examined the carcinogenic influence of low doses of DEN (6) . Approximately two-thousand 21-day-old male F344 rats were administered DEN at doses ranging from 0.0001 to 10 ppm in their drinking water for 16 weeks. No increase in number of GST-P positive foci was found at DEN doses of 0.0001-0.01 ppm; however, the number of GST-P positive foci was significantly elevated at 0.1 and 1 ppm DEN. In the 10 ppm group, the numbers of GST-P positive foci were so numerous that quantitation was not possible. Therefore, we concluded that NOEL for GST-P positive foci was 0.01 ppm, and the derived BMDL 1SD was 0.26 ppm. Furthermore, the value of BMDL 1SD was higher than that of NOEL.
Conclusions
Mode of action in chemical carcinogenesis is an important tool as qualitative analysis for the low dose carcinogenicity of genotoxic carcinogens. A summary of recent key in vivo findings obtained in experiments with several genotoxic carcinogens is presented in Table 2 . Quantitative analysis such as PoD may bring out the exposurerelated dose-sequence of each point in the initiation and promotion stages of carcinogenesis. Summary of results obtained from NOELs of markers in MeIQx-low dose hepatocarcinogenesis detected in our experiments is presented in Figure 5 . The formation of DNA-MeIQx adducts was observed at very low doses of MeIQx. Increasing the dose of MeIQx next resulted in elevation of 8-OHdG formation, gene mutation, cancer initiation activity (data not shown), and finally, at highest dose, an increase in the endpoint marker for carcinogenicity (GST-P positive foci). In case of IQ hepatocarcinogenesis, PoD of IQ-DNA adducts was much lower than that of GST-P positive foci. Thus, for examined genotoxic carcinogens, the NOELs for initiation markers (i.e. DNA adduct, 8-OHdG formations and gene mutation) were much lower than PoD for the promotion marker (i.e. preneoplastic lesions such as GST-P positive foci). It is worthy that MeIQx at doses which did not influence induction of promotion markers, also did not exert hepatocarcinogenicity in our 2-year carcinogenicity study (13) . These data demonstrate that increased doses of MeIQx were required as MeIQx-mediated effects moved from simple adduct formation to cellular metabolic changes to gene mutation and carcinogenesis initiation and promotion. It is strongly suggested that processes such as DNA repair, irreversible senescence, apoptosis and immune system function operate to inhibit the effects of genotoxic carcinogens, and that this inhibition is significant. From these data, we conclude that there may be thresholds, at least practical, for the carcinogens examined in our studies. The practical threshold concept is acceptable for mutagenic carcinogens which point mutations relate to carcinogenesis.
The debate on the existence of response thresholds for genotoxic chemical carcinogens is a long-standing one. It is gradually shifting away from the existence of thresholds towards pragmatic methods for the analysis of dose-response data, detection of PoD values, and extrapolation to environmentally relevant doses that are associated with negligible risk. It has been also suggested that genetic toxicity screening can be achieved through a combination of new techniques in genetic toxicology, together with quantitative dose-response analyses and the attendant extrapolations (14) . It has been accepted that for the establishment of PoDs from which the exposure-related risk can be estimated, there are two approaches to be used: NOEL approach and BMD approach (15) . In general, recent studies have indicated that quantitative BMD approach could be more preferable than the NOEL approach, as reported in recent reviewers of MacGregor and Johnson (14, 16) , and this conclusion was based in part on our data obtained in studies with MeIQx. Nevertheless, in case of MeIQx studies, BMD approach did not show the expected trend of PoDs for various endpoints in the hepatocarcinogenic process. Namely, the BMDL 1SD ranking was: 8-OHdG << DNA adducts formation < Mutation< GSTpositive foci. The values of BMD are smaller or higher than that of NOEL, and did not show uniform trend. On the other hand, in case of IQ and DEN, the values of BMD are greater than that of NOEL, and NOEL approach is preferable. Therefore, it could be recommended that the best approach must be decided case by case depending on the type of experiment and applied methods.
In conclusion, from our experiences, comparison of NOEL and BMD approaches demonstrates that neither NOEL approach nor BMD approach separately are applicable for all types of carcinogens, therefore, the most appropriate approach to use for dose-response assessment must be selected on the basis of scientific judgment.
Funding
These studies were supported by a grant from the Japan Science and Technology Corporation, included in the Project of Core Research for Evolutional Science and Technology (CREST) and by a grant from the Ministry of Education, Culture, Sports, Science and Technology of Japan.
